Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

593
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
593

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploratory Prospective Study of Self-Titrated Medical Cannabis for Nonmotor Symptoms in Parkinson's Disease.

Cannabis and cannabinoid research·2026
Same author

Medical cannabis treatment non-adherence among oncology patients: A prospective cohort analysis in Israel.

European journal of oncology nursing : the official journal of European Oncology Nursing Society·2026
Same author

Efficacy, effectiveness and safety of medical cannabis in PTSD: a scoping review.

Journal of cannabis research·2026
Same author

Complete biosynthesis of psychedelic tryptamines from three kingdoms in plants.

Science advances·2026
Same author

Development and Characterization of a High-CBD Cannabis Extract Nanoemulsion for Oral Mucosal Delivery.

International journal of molecular sciences·2025
Same author

Combination of CBD with minor cannabinoid CBDV suppresses CXCR4 via CB2 receptor and alleviates colitis in mice.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025

Related Experiment Video

Updated: Dec 18, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.6K

Migraine Frequency Decrease Following Prolonged Medical Cannabis Treatment: A Cross-Sectional Study.

Joshua Aviram1, Yelena Vysotski1, Paula Berman1

  • 1Technion-Israel Institute of Technology, Faculty of Biology, Haifa 3200003, Israel.

Brain Sciences
|June 13, 2020
PubMed
Summary
This summary is machine-generated.

Medical cannabis (MC) treatment for migraine shows long-term benefits, with over 60% of patients experiencing reduced migraine frequency. This treatment is linked to decreased disability and lower intake of other migraine medications.

Keywords:
cannabinoidsdisabilitymigraine: chronic painopioidstriptans

More Related Videos

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

7.3K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.2K

Related Experiment Videos

Last Updated: Dec 18, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.6K
Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

7.3K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.2K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Medical cannabis (MC) is an emerging treatment for migraine, but clinical data remain limited.
  • This study investigates the relationship between phytocannabinoid treatment and migraine frequency.

Purpose of the Study:

  • To assess the efficacy of medical cannabis in reducing migraine frequency.
  • To identify differences in MC use and outcomes between responders and non-responders.

Main Methods:

  • A cross-sectional, questionnaire-based study of 145 migraine patients licensed for MC treatment.
  • Patients were classified as responders (≥50% reduction in monthly migraine attacks) or non-responders (<50% reduction).
  • Comparative statistics analyzed differences in demographics, MC use, and clinical outcomes between subgroups.

Main Results:

  • 61% of patients were classified as responders, reporting significantly lower migraine disability and negative impact.
  • Responders consumed higher doses of phytocannabinoid ms_373_15c and lower doses of ms_331_18d.
  • Responders showed reduced consumption of opioids and triptans compared to non-responders.

Conclusions:

  • Medical cannabis provides a long-term reduction in migraine frequency for over 60% of patients.
  • MC treatment is associated with decreased migraine-related disability and reduced reliance on other migraine medications.
  • Specific phytocannabinoid compositions may hold potential efficacy for migraine management.